Biosimilars and cancer treatment of older patients Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Biosimilar Pharmaceuticals
  • Neoplasms

abstract

  • Biosimilar monoclonal antibodies are being developed globally to meet clinical demand in oncology and potentially provide greater access to biologic therapies for patients with cancer, including older patients. In this supplement, we present an overview of the development, approval requirements, and characteristics of biosimilar monoclonal antibodies that may help practicing oncologists and other healthcare providers to acquire familiarity with this new group of therapeutic biologic agents. Furthermore, we review and discuss some of the challenges and potential strategies for the management of older patients with cancer, who represent an increasing population in many countries.

publication date

  • March 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.jgo.2016.01.002

PubMed ID

  • 26856525

Additional Document Info

start page

  • S1

end page

  • 8

volume

  • 7

number

  • 1